Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A

被引:55
作者
Soyama, A
Hanioka, N
Saito, Y
Murayama, N
Ando, M
Ozawa, S
Sawada, J
机构
[1] Natl Inst Hlth Sci, Div Environm Chem, Setagaya Ku, Tokyo 1588501, Japan
[2] Natl Inst Hlth Sci, Project Team Pharmacogenet, Setagaya Ku, Tokyo 1588501, Japan
[3] Natl Inst Hlth Sci, Div Biochem & Immunochem, Setagaya Ku, Tokyo 1588501, Japan
[4] Natl Inst Hlth Sci, Div Pharmacol, Setagaya Ku, Tokyo 1588501, Japan
来源
PHARMACOLOGY & TOXICOLOGY | 2002年 / 91卷 / 04期
关键词
D O I
10.1034/j.1600-0773.2002.910404.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Amiodarone is a potent Class III antiarrhythmic drug. The N-deethylation of amiodarone to desethylamiodarone is known to be catalyzed by cytochrome P450 (CYP) 2C8. In the present study, amiodarone N-deethylation by the CYP2C8s, CYP2C8*1 (wild-type), CYP2C8*3, and CYP2C8 P404A (Pro404Ala substitution in exon 8), was investigated by their transient expression in Hep G2 cells. The expression levels of CYP2C8*1 and CYP2C8*3 were similar, whereas the level of CYP2C8 P404A was 55.6% of that of CYP2C8*1. The kinetic parameters of amiodarone N-deethylation were obtained by means of Lineweaver-Burk analysis. The intrinsic clearance (V-max/K-m, per mg of microsomal protein) of amiodarone by CYP2C8 P404A but not CYP2C8*3 was significantly (48.7%) less than that of CYP2C8*1. These results suggest that CYP2C8 P404A but not CYP2C8*3 is less effective in the N-deethylation of amiodarone.
引用
收藏
页码:174 / 178
页数:5
相关论文
共 18 条
[1]   Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid [J].
Dai, D ;
Zeldin, DC ;
Blaisdell, JA ;
Chanas, B ;
Coulter, SJ ;
Ghanayem, BI ;
Goldstein, JA .
PHARMACOGENETICS, 2001, 11 (07) :597-607
[2]  
FABRE G, 1993, DRUG METAB DISPOS, V21, P978
[3]   The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6 [J].
Fukuda, T ;
Nishida, Y ;
Imaoka, S ;
Hiroi, T ;
Naohara, M ;
Funae, Y ;
Azuma, J .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 380 (02) :303-308
[4]  
HARRIS L, 1986, AMIODARONE
[5]   AMIODARONE PHARMACOKINETICS [J].
HOLT, DW ;
TUCKER, GT ;
JACKSON, PR ;
STOREY, GCA .
AMERICAN HEART JOURNAL, 1983, 106 (04) :840-847
[6]  
JOHANSSON I, 1994, MOL PHARMACOL, V46, P452
[7]   ELECTROPHYSIOLOGIC EFFECTS OF DESETHYLAMIODARONE, AN ACTIVE METABOLITE OF AMIODARONE - COMPARISON WITH AMIODARONE DURING CHRONIC ADMINISTRATION IN RABBITS [J].
KATO, R ;
VENKATESH, N ;
KAMIYA, K ;
YABEK, S ;
KANNAN, R ;
SINGH, BN .
AMERICAN HEART JOURNAL, 1988, 115 (02) :351-359
[8]  
LUDERITZ B, 1991, J CARDIOVASC PHARM, V17, pS48
[9]  
Ohyama K, 2000, DRUG METAB DISPOS, V28, P1303
[10]   RESTING, AND RATE-DEPENDENT DEPRESSION OF VMAX OF GUINEA-PIG VENTRICULAR ACTION-POTENTIALS BY AMIODARONE AND DESETHYLAMIODARONE [J].
PALLANDI, RT ;
CAMPBELL, TJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1987, 92 (01) :97-103